SOURCE-LINKED STUDY SUMMARY
Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial.
Full paper summarizedQuality not appraised
- What was studied
- A randomized pilot tested behavioral-app support or medically tailored meals versus usual care after GLP-1 treatment stopped.
- Who / model studied
- 39 adults with prior GLP-1-associated weight loss; 34 completed a final weigh-in.
- Studied dose & schedule
- Four months of a Noom subscription, 10 tailored meals weekly, or provider-directed usual care.
- What the study found
- Estimated weight gain was 10.75% with usual care, 3.60% with the app and 3.58% with meals. Adherence, satisfaction, diet quality and perceived health did not significantly differ. No harms were reported.
- Limitations & context
- Weight was exploratory; the small pilot was not powered for definitive efficacy. Follow-up was short and usual care varied. All groups regained weight, and results do not establish durable maintenance.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1002/osp4.70194